High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and ...

A meta-analysis involving more than 6000 men suggested that adding hormone therapy (HT) to radiation after radical prostatectomy improves overall survival (OS) in those with higher pre-radiation ...

Prostate cancer relapse treatment could be cut from 35 visits to just five. See how new radiation technology may change your ...

When I had my prostate removed in September 2023, I believed the worst was behind me. After months of tests, scans and ...

Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...

Annalisa (Nalis) Merelli is focused on boys’ and men’s health: She looks into reproductive health, trending treatments, screening approaches, mental health, and everything in between.

Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two ...

A 65-year-old male patient initially presented with a PSA of 10 ng/mL. A 65-year-old male patient initially presented with a PSA of 10 ng/mL. He ultimately underwent a prostate needle biopsy, with 3 ...